Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DNTH with free AI briefings, catalyst countdowns, and dilution alerts.

DNTH · Dianthus Therapeutics, Inc. /DE/

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.2B Cash on Hand
75.1mo Cash Runway
Follow DNTH by email Get an email when DNTH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DNTH, unsubscribe in one click. Privacy

📣 What DNTH Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Claseprubart Chronic Inflammatory Demyelinating Polyneuropathy Phase 3 · NCT06858579 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DNTH holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $49.7M/quarter from operations, an estimated runway of 75.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DNTH files for a raise →

👥 Who Owns DNTH

Insiders 0.1% Institutions (384 holders) 99.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 5,885,888 10.45% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 3,504,166 6.22% 2026-06-30
Wellington Management Group LLP Institution (13G, 5%+) 3,229,882 5.74% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 2,846,786 5.06% 2026-09-30
Marino Garcia
CEO AND PRESIDENT, Director · +904,453 options
Insider 65,292 0.12% 2026-08-07
Adam M Veness
SVP, General Counsel and Sec. · +233,240 options
Insider 15,000 0.03% 2026-08-13
Simrat Randhawa
EVP, Head of R&D · +395,952 options
Insider 4,000 0.01% 2026-09-01

Share count 56,312,712 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full DNTH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DNTH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.